PTPN22 gene associated with both susceptibility and disease progression in rheumatoid arthritis

June 22, 2006

New research, announced today at the 7th EULAR annual congress, reveals the Protein Tyrosine Phosphatase N22 (PTPN22) gene is associated not only with rheumatoid arthritis (RA) disease susceptibility, but also with disease progression, according to researchers from Norway and the Netherlands.

Whilst the missense polymorphism (1858C>T ; rs2476601) in the PTPN22 gene has recently been shown to be associated with risk of developing rheumatoid arthritis, as well as some other autoimmune diseases (such as lupus and type 1 diabetes), the potential influence of the gene on clinical outcomes has previously been unclear. As such, the study team aimed to investigate the extent to which the PTPN22 polymorphism was associated with the presence of autoantibodies and rate of radiographic progression in rheumatoid arthritis.

The team genotyped a cohort of 238 Norwegian rheumatoid arthritis patients (56% RF positive, aged between 20 to 70 years, with an average disease duration of 2.3 years). Radiographic damage was assessed by hand radiographs scored with the van der Heijde modified Sharp score (vdH Sharp score) by one reader.

Results from the study revealed RA association with carriage of the T allele (34.6 % in patients vs 21.4 % in controls; OR=1.94 (1.35-2.79), p= 0.0003) as well as an association between annual progression rate of vdH Sharp score and T-allele carriers (p=0.01).

No significant association was observed between the presence of the T-allele and either RF status (36% in RF+ vs 33% in RF-) or anti-CCP status (37% in anti-CCP+ vs 31% in anti-CCP-). To look for evidence of epistasis between PTPN22 and DRB1, the team also stratified for presence or absence of the shared epitope (SE), however no difference was seen between the two groups.

"Results from this study reveal the PTPN22 gene risk variant was associated with the progression rate for the articular damage" explained Dr. Benedicte Lie, Institute of Immunology, Rikshospitalet University Hospital, Oslo, Norway, and the study's lead author. "Our findings indicate that this candidate gene is associated not only with disease susceptibility, but also with disease progression - a potentially valuable discovery in the search for effective treatments to treat and ultimately prevent onset of rheumatoid arthritis" she continued.
For further information on this study, or to request an interview with the study lead, please do not hesitate to contact the EULAR congress press office on:


Jim Baxter - Onsite tel: +44 (0) 7900 605652
Jo Spadaccino - Onsite tel: +44 (0) 7773 271930
Mia Gannedahl - Office tel: +44 (0) 20 7331 2325

Abstract number: OP0068


European League Against Rheumatism

Related Rheumatoid Arthritis Articles from Brightsurf:

Reducing dementia in patients with rheumatoid arthritis
The incidence of dementia in patients with rheumatoid arthritis is lower in patients receiving biologic or targeted synthetic disease modifying antirheumatic drugs (DMARDs) than in patients who receive conventional synthetic DMARDs, according to a new study.

Is rheumatoid arthritis two different diseases?
While disease activity improves over time for most rheumatoid arthritis (RA) patients, long-term outcomes only improve in RA patients with autoantibodies, according to a new study published this week in PLOS Medicine by Xanthe Matthijssen of Leiden University Medical Center, Netherlands, and colleagues.

Does the Mediterranean diet protect against rheumatoid arthritis?
Previous research has demonstrated a variety of health benefits associated with the Mediterranean diet, which is rich in olive oil, cereals, fruit and vegetables, fish, and a moderate amount of dairy, meat, and wine.

Reducing corticosteroid use in rheumatoid arthritis
Is the long-term use of glucocorticoids essential in people with chronic inflammatory diseases such as rheumatoid arthritis, or can early discontinuation prevent characteristic side effects?

Rheumatoid arthritis patients under treatment with methotrexate
Patients with rheumatoid arthritis (RA) often suffer from what is referred to as interstitial lung disease (ILD).

Rheumatoid arthritis -- can its onset be delayed or prevented?
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disorder that leads to significant health issues as well as high treatment costs.

Disease burden in osteoarthritis is similar to rheumatoid arthritis
Osteoarthritis (OA) has traditionally been viewed as a highly prevalent but milder condition when compared with rheumatoid arthritis (RA), and some may believe that it is part of a normal aging process requiring acceptance, not treatment.

Prospect of a new treatment for rheumatoid arthritis
An international research group led by Charité -- Universitätsmedizin Berlin has completed testing a new drug to treat rheumatoid arthritis.

Can rare lymphocytes combat rheumatoid arthritis?
Immunologists at Friedrich-Alexander-Universität Erlangen-Nürnberg have demonstrated that ILC2, a group of rare lymphoid cells, play a key role in the development of inflammatory arthritis.

Rheumatoid arthritis meets precision medicine
Scientists are bringing precision medicine to rheumatoid arthritis for the first time by using genetic profiling of joint tissue to see which drugs will work for which patients, reports a new multi-site study.

Read More: Rheumatoid Arthritis News and Rheumatoid Arthritis Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to